US 11,999,710 B2
Radiolabeled cannabinoid receptor 2 ligand
Simon M. Ametamey, Zurich (CH); Luca Gobbi, Basel (CH); Uwe Grether, Basel (CH); Julian Kretz, Basel (CH); Dieter Muri, Basel (CH); and Ahmed Haider Wahauib, Zurich (CH)
Assigned to HOFFMANN-LA ROCHE INC., Little Falls, NJ (US); and ETH ZUERICH, Zurich (CH)
Filed by HOFFMANN-LA ROCHE INC., Little Falls, NJ (US); and ETH ZUERICH, Zurich (CH)
Filed on Dec. 17, 2020, as Appl. No. 17/125,655.
Application 17/125,655 is a continuation of application No. PCT/EP2019/066799, filed on Jun. 25, 2019.
Claims priority of application No. 18180154 (EP), filed on Jun. 27, 2018.
Prior Publication US 2021/0115012 A1, Apr. 22, 2021
Int. Cl. C07D 401/04 (2006.01); C07B 59/00 (2006.01)
CPC C07D 401/04 (2013.01) [C07B 59/002 (2013.01); C07B 2200/05 (2013.01)] 23 Claims
 
1. A compound of formula (I)

OG Complex Work Unit Chemistry
wherein
A is CH or N;
R1 and R2 are both ethyl at the same time; and
R3 is fluoropropyl or hexadeuteriofluoropropyl;
provided that at least one of R1, R2 and R3 comprises at least one radionuclide;
or a pharmaceutically acceptable salt thereof.